Cargando…
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed death ligand 1 (PD-L1) demonstrated outstanding clinical activity. Translational investigations also suggested some correlatio...
Autores principales: | Evrard, D., Hourseau, M., Couvelard, A., Paradis, V., Gauthier, H., Raymond, E., Halimi, C., Barry, B., Faivre, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714503/ https://www.ncbi.nlm.nih.gov/pubmed/33299655 http://dx.doi.org/10.1080/2162402X.2020.1844403 |
Ejemplares similares
-
Somatic 9p24.1 alterations in HPV(–) head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity
por: Zhao, Xin, et al.
Publicado: (2022) -
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Burcher, Kimberly M., et al.
Publicado: (2021) -
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021) -
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021) -
PD-1/PD-L1 expression in anal squamous intraepithelial lesions
por: Bucau, Margot, et al.
Publicado: (2020)